Join our daily newsletter At The Bell to receive exclusive market insights
- Heramed’s (HMD) at-home maternity care technologies will undergo further clinical studies with prominent nonprofit medical centre Mayo Clinic
- These will be the second clinical studies for the HeraBEAT device following “outstanding” results at preceding trials in West Australia
- The clinical study is expected to commence in the coming weeks at a Mayo Clinic in Rochester, Minnesota and will assess the solution’s functionality and acceptability when self-administered by pregnant women at home
- The HeraBEAT product monitors foetal and maternal heart rate through a smartphone interface while the HeraCARE platform enables the measurements to be shared with healthcare professionals
- The study is set to commence December 2020 and conclude in October 2021
- Heramed shares closed in the grey trading at 13 cents each
HeraMED’s (HMD) at-home maternity care technologies will undergo further clinical studies with prominent nonprofit medical centre Mayo Clinic.
The trials follow what the company coins as “outstanding” results from a previous HeraBEAT trial at the Joondalup Health Campus in Perth, which found the device could detect a foetus’ heart rate with 100 per cent efficiency.
The clinical study is expected to commence in the coming weeks at a Mayo Clinic in Rochester, Minnesota and will assess the solution’s functionality, usability and user acceptability.
The HeraBEAT device uses a smartphone interface to determine both foetal and maternal heart rates, which can then be evaluated and monitored by a medical professional via the HeraCARE platform.
There will be 50 low-risk expectant mothers as part of the trial who will evaluate the impact of the device on their perception of foetal wellbeing through standardised surveys.
HeraMED Chief Executive and Co-founder David Groberman says the Mayo Clinic trial is a precursor to a broader HeraCARE pilot.
“Our strategy is to cooperate with top-tier healthcare providers to drive adoption and this clinical study represents an extension to our existing collaboration with Mayo Clinic and aligns perfectly with our strategic goals,” he commented.
The study is expected to commence December 2020 with an estimated conclusion in October 2021.
HeraMED shares closed in the grey trading at 13 cents each.
